Evidence map›Paper›PMID 34051040›Full record

ArticleLiver international : official journal of the International Association for the Study of the Liver2021

The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis.

Peng Huang, Yan Wang, Ming Yue, Zhijun Ge, Xueshan Xia, Andre J Jeyarajan, Jacinta A Holmes, Rongbin Yu, Chuanwu Zhu, Sheng Yang and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver international : official journal of the International Association for the Study of the Liver, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 3 countries.

Peng HuangDepartment of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.ORCID 0000-0002-0146-921X
Yan WangDepartment of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.ORCID 0000-0002-1137-9971
Ming YueDepartment of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zhijun GeDepartment of Critical Care Medicine, The Affiliated Yixing Hospital of Jiangsu University, Yixing, China.
Xueshan XiaFaculty of Life Science and Technology, Kunming University of Science and Technology of Science and Technology, Kunming, China.
Andre J JeyarajanLiver Center and Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-6308-0859
Jacinta A HolmesDepartment of Gastroenterology, St. Vincent's Hospital, Fitzroy, Victoria, Australia.
Rongbin YuDepartment of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Chuanwu ZhuDepartment of Hepatology, The Fifth People's Hospital of Suzhou, Suzhou, China.
Sheng YangDepartment of Biostatistics, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.ORCID 0000-0003-3657-8771
Wenyu LinLiver Center and Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Raymond T ChungLiver Center and Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Harvard University · USNanjing Medical University · CNJiangsu Province Hospital · CNJiangsu University · CNKunming University of Science and Technology · CNSt Vincent's Hospital Melbourne · AUThe Fifth People’s Hospital of Suzhou · CN

Funding

Virology CoreU19AI082630 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI GEORG Michael LAUER · 2009 to 2026
$48.1M
Cooperative mechanisms of HIV-enhanced liver fibrogenesis in HBV CoinfectionR01AI155140 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T, LIN, WENYU · 2020 to 2025
$3.5M
HIV, HCV, Hippo, and Liver Disease ProgressionR01AI136715 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T · 2018 to 2022
$3.4M
HIV-Associated Macrophage Alterations and Progressive Liver DiseaseR01DK108370 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T · 2015 to 2019
$1.6M
NIAID NIH HHS R01 AI136715NIAID NIH HHS R01 AI155140NIAID NIH HHS U19 AI082630NIDDK NIH HHS R01 DK108370
6 · The paper itself

Abstract

BACKGROUND &

aimsThe risk for hepatitis C virus (HCV) recurrence persists after HCV eradication with direct-acting antivirals (DAAs), particularly in patients with ongoing high-risk behaviours. Our aim was to assess the risk of HCV recurrence (late relapse and/or reinfection) post-sustained virological response (SVR).

methodsWe searched the literature for studies reporting HCV recurrence rates post-SVR in PubMed, Web of Science and the Cochrane Library. Identified publications were divided into groups based on patient risk for HCV reinfection: low-risk HCV mono-infection, high-risk HCV mono-infection and a human immunodeficiency virus (HIV)/HCV coinfection. The HCV recurrence rate for each study was calculated by using events divided by the person-years of follow-up (PYFU). HCV recurrence was defined as confirmed, detectable HCV RNA post-SVR.

resultsIn the 16 studies of low-risk patients, the pooled recurrence rate was 0.89/1000 PYFU (95% confidence interval [CI], 0.16-2.03). For the 19 studies of high-risk patients, the pooled recurrence rate was 29.37/1000 PYFU (95% CI, 15.54-46.91). For the eight studies of HIV/HCV-coinfected patients, the pooled recurrence rate was 23.25/1000 PYFU (95% CI, 4.24-53.39). The higher pooled estimates of recurrence in the high-risk and HIV/HCV-coinfected populations were predominantly driven by an increase in reinfection rather than late relapse.

conclusionsThe HCV recurrence risk after achieving SVR with all-oral DAAs therapy is low, and the risk of HCV recurrence in high-risk and HIV/HCV-coinfected populations was driven by an increase in reinfection rather than late relapse.

Indexed as

CoinfectionHepatitis CHepatitis C, ChronicHIV InfectionsAntiviral AgentsHepacivirusHumansRecurrenceSustained Virologic ResponseAntiviral Agentsdirect-acting antiviralshepatitis C virusreinfectionrelapsesustained virological response

Identifiers

PMID34051040
PMCPMC8455436
OpenAlexW3165799749

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.